Role of HMGB1 and its associated signaling pathways in human malignancies.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 07 2023
revised: 11 09 2023
accepted: 22 09 2023
medline: 3 11 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

The High-Mobility Group Box-1 (HMGB1), a non-histone chromatin-associated protein, plays a crucial role in cancer growth and response to therapy as it retains a pivotal role in promoting both cell death and survival. HMGB1 has been reported to regulate several signaling pathways engaged in inflammation, genome stability, immune function, cell proliferation, cell autophagy, metabolism, and apoptosis. However, the association between HMGB1 and cancer is complex and its mechanism in tumorigenesis needs to be further elucidated. This review aims to understand the role of HMGB1 in human malignancies and discuss the signaling pathways linked to this process to provide a comprehensive understanding on the association of HMGB1 with carcinogenesis. Further, we will review the role of HMGB1 as a target/biomarker for cancer therapy, the therapeutic strategies used to target this protein, and its potential role in preventing or treating cancers. In light of the recent growing evidence linking HMGB1 to cancer progression, we think that it may be suggested as a novel and emergent therapeutic target for cancer therapy. Hence, HMGB1 warrants paramount investigation to comprehensively map its role in tumorigenesis.

Identifiants

pubmed: 37757902
pii: S0898-6568(23)00319-4
doi: 10.1016/j.cellsig.2023.110904
pii:
doi:

Substances chimiques

HMGB1 Protein 0
HMGB1 protein, human 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110904

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that this work was conducted in the absence of any financial relationships that could be construed as a potential conflict of interest.

Auteurs

Sourour Idoudi (S)

Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.

Takwa Bedhiafi (T)

College of Pharmacy, Qatar University, Doha, Qatar.

Shona Pedersen (S)

Department of Basic Medical Science, College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.

Mohamed Elahtem (M)

College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.

Izzaldin Alremawi (I)

College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.

Sabah Akhtar (S)

Department of Dermatology and venereology, Hamad Medical Corporation, Doha, Qatar; Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Said Dermime (S)

Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.

Maysaloun Merhi (M)

Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. Electronic address: mmerhi@hamad.qa.

Shahab Uddin (S)

Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Laboratory Animal Research Center, Qatar University, Doha, Qatar. Electronic address: Skhan34@hamad.qa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH